Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX66 plus nivolumab in adults with advanced solid tumors
ACTRN12621001537842Phase 2Recruiting
- Sponsor
- Cancer Care Foundation
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of NOX66 and nivolumab in Nonhematologic neoplasms, sponsored by Cancer Care Foundation. Started Oct 2021; status: recruiting.
02
Drugs
NOX66nivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12621001537842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001537842.